The reliability of data collection periods of personal costs associated with vision impairment

Ophthalmic Epidemiology

Volumn 13, Issue 2, 2006, Pages 121-126

  Lamoureux, E L ^a   Chou, S L ^a   Larizza, M F ^a   Keeffe, J E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Data collection reliability; Diaries; Personal costs; Vision impairment

Indexed keywords

ADULT; AGE; AGED; ARTICLE; AUDIO RECORDING; BRAILLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTRONICS; EYE; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HUMAN; MALE; PRINTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY; RETINA MACULA AGE RELATED DEGENERATION; SOCIAL ASPECT; SOCIAL WELFARE; VISUAL ACUITY; VISUAL IMPAIRMENT;

COST OF ILLNESS; DATA COLLECTION; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; VISION, LOW;

EID: 33645650275     PISSN: 09286586     EISSN: 17445086     Source Type: Journal    
DOI: 10.1080/09286580500536781     Document Type: Article

References (12)

1. Taylor HR, Keeffe JE, Vu HTV, et al. Vision loss in Australia. Med J Aust. 2005;182:565-568.
2. The Eye Diseases Prevalence Research group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-485.
3. Lamoureux EL, Hassell B, Keeffe JE. The determinants of participation in activities of daily living in people with visual impairment. Am J Ophthalmol. 2004;137:265-270.
4. Weih L, Hassell JB, Keeffe JE. Assessment of the impact of vision impairment. Invest Ophthalmol Vis Sci. 2002;43:927-935.
5. Frick KD, Foster A. The magnitude and cost of global blindness: an increasing problem that can be alleviated. Am J Ophthalmol. 2003:135:471-476.
6. Smith DH, Fenn P, Drummond M. Cost effectiveness analysis of photodynamic therapy with verteporfin for age-related macular degeneration: the UK case. Br J Ophthalmol. 2004;88:1107-1112.
7. Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol. 2004;88:982-987.
8. Royal National Institute for the Blind. The Costs of Blindness: Examining the Extra Financial Costs Resulting From Visual Impairment. ISBN 1 85878 212 0. London: Royal National Institute for the Blind, 2000.
9. Sach TH, Whynes DK. Measuring indirect costs: is there a problem? Appl Health Econ Health Policy. 2003;2(3):135-139.
10. Freer CB. Self-care: a health diary study. Med Care. 1980;18:853-861.
11. Goossens EJB, Rutten-Van Molken MPMH, Vlaeyen JWS, Van der Linden SMJP. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol. 2000;53:688-695.
12. Access Economics. Clear Insight: the Economic Impact and Cost of Vision Loss in Australia. Melbourne: Eye Research Australia, 2004.